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  32 
  The congenital long QT syndrome (LQTS) is a cardiac electrophysiological disorder 33 
that can cause sudden cardiac death. LQT1 is a subtype of LQTS caused by mutations in 34 
KCNQ1, affecting the slow delayed-rectifier potassium current (IKs), which is essential for 35 
cardiac repolarization. Paradoxically, gain-of-function mutations in KCNQ1 have been 36 
reported to cause borderline QT prolongation, atrial fibrillation (AF), sinus bradycardia, and 37 
sudden death, however, the mechanisms are not well understood. The goal of the study is to 38 
investigate the ionic, cellular and tissue mechanisms underlying the complex phenotype of a 39 
gain-of-function mutation in KCNQ1, c.686G>A (p.G229D) using computer modelling and 40 
simulations informed by in vitro measurements. Previous studies have shown this mutation to 41 
cause AF and borderline QT prolongation. We report a clinical description of a family that 42 
carry this mutation and that a member of the family died suddenly during sleep at 21 years old. 43 
Using patch-clamp experiments, we confirm that KCNQ1-G229D causes a significant gain in 44 
channel function. We introduce the effect of the mutation in populations of atrial, ventricular 45 
and sinus node (SN) cell models to investigate mechanisms underlying phenotypic variability. 46 
In a population of human atrial and ventricular cell models and tissue, the presence of KCNQ1-47 
G229D predominantly shortens atrial action potential duration (APD). However, in a subset of 48 
models, KCNQ1-G229D can act to prolong ventricular APD by up to 7% (19ms) and underlie 49 
depolarization abnormalities, which could promote QT prolongation and conduction delays. 50 
Interestingly, APD prolongations were predominantly seen at slow pacing cycle lengths 51 
(CL>1000ms), which suggests a greater arrhythmic risk during bradycardia, and is consistent 52 
with the observed sudden death during sleep. In a population of human SN cell models, the 53 
KCNQ1-G229D mutation results in slow/abnormal sinus rhythm, and we identify that a 54 
stronger L-type calcium current enables the SN to be more robust to the mutation. In conclusion, 55 
our computational modelling experiments provide novel mechanistic explanations for the 56 
observed borderline QT prolongation, and predict that KCNQ1-G229D could underlie SN 57 
dysfunction and conduction delays. The mechanisms revealed in the study can potentially 58 
inform management and treatment of KCNQ1 gain-of-function mutation carriers. 59 
 60 
 61 
1. INTRODUCTION 62 
 63 
 Long QT Syndrome (LQTS) is a type of cardiac disorder that is often related to syncope 64 
and sudden cardiac death. LQT1, which is the most common form of LQTS, is caused by 65 
mutations in the KCNQ1 gene, affecting the slow delayed-rectifier repolarizing current (IKs) 66 
(Barhanin et al. 1996; Sanguinetti et al. 1996). Loss-of-function mutations in KCNQ1 can 67 
reduce IKs and underlie the inherited form of long QT syndrome (LQT1) (Wang et al. 1996), 68 
while gain-of-function mutations in KCNQ1 can act to increase channel opening, resulting in 69 
enhanced IKs (Hong et al. 2005; Moreno et al. 2015; Chen et al. 2003; Lundby et al. 2007; Das 70 
et al. 2009; Bartos et al. 2011; Bartos et al. 2013; Ki et al. 2014).  71 
 72 
Gain-of-function mutations in KCNQ1 associate with complex phenotypes. To date, 73 
eight gain-of-function mutations in KCNQ1 have been identified that underlie persistent 74 
familial atrial fibrillation (AF) (Hancox et al. 2014; Hasegawa et al. 2014), and four have been 75 
reported to cause short QT syndrome type 2 (SQT2) (Bellocq et al. 2004; Hong et al. 2005; 76 
Moreno et al. 2015; Wu et al. 2015). Some of these gain-of-function mutations are additionally 77 
associated with sinus bradycardia (S140G (Chen et al. 2003), V141M (Hong et al. 2005), 78 
R231C (Henrion et al. 2012), V241F (Ki et al. 2014) and F279I (Moreno et al. 2015)), and 79 
paradoxically, some KCNQ1 gain-of-function mutations have been linked to QT prolongation 80 
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(borderline LQT) (S140G (Chen et al. 2003), Q147R (Lundby et al. 2007), R231C (Bartos et 81 
al. 2011; Henrion et al. 2012) and R231H (Bartos et al. 2013)). The mechanisms underlying 82 
how certain KCNQ1 gain-of-function mutations cause AF and SQT2 have been revealed by 83 
in-silico studies. In general, the gain in IKs function acts to shorten the refractory period and 84 
stabilize re-entrant waves, therefore promoting atrial fibrillation and ventricular arrhythmia 85 
(Kharche et al. 2012; Adeniran et al. 2017; Zulfa et al. 2016). In addition, the effects of several 86 
gain-of-function KCNQ1 mutations (V141M, R231C and V241F) on sinus bradycardia have 87 
recently been explored using human in silico models of the sinus node (SN) (Fabbri et al. 2017; 88 
Whittaker et al. 2018). However, the mechanisms that underlie why certain KCNQ1 gain-of-89 
function mutations are associated with borderline LQT and the factors that may explain 90 
phenotypic variability remain unclear.  91 
 92 
 The goal of this study is to investigate the ionic, cellular and tissue mechanisms 93 
underlying the complex phenotype of a gain-of-function mutation in KCNQ1, p.G229D 94 
(c.686G>A), (KCNQ1-G229D) using human atrial, ventricular and sinus node (SN) models 95 
informed by in vitro patch-clamp measurements. This mutation was first reported in 2014 in a 96 
16-year-old boy with AF (Hasegawa et al. 2014). Interestingly, after radiofrequency catheter 97 
ablation therapy sinus rhythm was maintained, but the boy represented with borderline LQT 98 
(Hasegawa et al. 2014). Here, we report the clinical features of members of a British family 99 
affected by the same mutation. In addition to AF and borderline LQT, sudden death also 100 
happened in this family. By using a population of models approach, we investigate how natural 101 
variations in ionic current density could underlie variability in the phenotype of mutation 102 
carriers. In particular, we focus on the mechanisms that underlie the associated borderline LQT, 103 
which has also been reported for other KCNQ1 gain-of-function mutations but has not been 104 
explored. In addition, we investigate potential effects on the SN, based on the SN dysfunction 105 
caused by other KCNQ1 gain-of-function mutations. 106 
 107 
2. MATERIALS AND METHODS 108 
 109 
2.1 Clinical data and QT interval duration assessment  110 
The clinical characterisation of the family carrying the G229D mutation was carried 111 
out in accordance with the recommendations of the National Health Service (NHS) Health 112 
Research Authority. The protocol was approved by the National Research Ethics Service 113 
(NRES Committee) East Midlands - Nottingham 2 [Research Ethics Committee (REC) 114 
reference: 09/H0508/74]. All subjects gave written informed consent in accordance with the 115 
Declaration of Helsinki. QT interval duration was measured on resting electrocardiograms 116 
(ECGs) using lead V5 or II (Figure 1). In patients in sinus rhythm an average of three 117 
consecutive beats was calculated. In patients with AF an average of six consecutive beats was 118 
calculated. The Bazett formula (Bazett 1920) was used to correct QT according to heart rate 119 
(QTc).  120 
 121 
2.2 Molecular biology and cell culture 122 
We characterised the effects of the G229D mutation on KCNQ1/KCNE1 (IKs) channel 123 
function by whole-cell patch-clamp in a heterologous expression system (Chinese Hamster 124 
Ovary-K1 (CHO-K1) cells). KCNQ1 (GenBank® accession number AF000571) and KCNE1 125 
are as described in (Harmer et al. 2014). pEGFP-N1 was from Clontech. The patient-identified 126 
G229D mutation (c.686G>A) was introduced into KCNQ1 using site-directed mutagenesis 127 




CHO-K1 cells (Sigma Aldrich, 85051005) were cultured as described in (Harmer et al. 130 
2014). To analyse the effects of G229D, cells were transfected with 250 ng of wild-type (WT) 131 
KCNQ1 or LQT1 mutant cDNA and 500 ng of KCNE1 (+50 ng pEGFP-N1) (IKs-WT or IKs-132 
G229D respectively). To mimic the heterozygous patient phenotype (IKs-HET), cells were 133 
transfected with 125 ng of wild-type channel + 125 ng of mutant channel and 500 ng KCNE1 134 
(+50 ng pEGFP-N1). Transfections were performed as described in (Harmer et al. 2014). After 135 
transfection, cells were split at low density onto 10mm glass coverslips and transfected cells 136 
(identified by fluorescence) were patched 48 hours later.  137 
 138 
2.3 Patch-clamp electrophysiological recording and analysis   139 
Whole-cell currents were recorded using an Axopatch 200B amplifier (Axon 140 
Instruments/Molecular Devices). Data acquisition was performed using pCLAMP10 software 141 
through a Digidata 1440A (Axon Instruments/Molecular Devices). Data digitization 142 
(sampling) rates were 0.5 kHz and recordings were lowpass Bessel filtered at 1 kHz.  143 
Whole-cell patch-clamp: For the experiments detailed in Figure 2 whole-cell patch-144 
clamp recording was performed at room temperature (22 C) as described in (Thomas et al. 145 
2011). The intracellular (pipette) solution contained: (mmol/L) 150 KCl, 10 HEPES, 5 EGTA, 146 
2 MgCl2, 1 CaCl2 and 5 (Na)2ATP (pH 7.2 with KOH). The extracellular (bath) solution 147 
contained: (mmol/L) 150 NaCl, 5 KCl, 10 HEPES, 2 MgCl2 and 1 CaCl2 (pH 7.4 with NaOH). 148 
Pipette resistances were, once filled with intracellular solution, between 2-3 mega-ohms (M). 149 
Pipette capacitance was reduced by coating the pipette tip with SigmaCote (SL2, Sigma). Once 150 
the whole-cell configuration had been achieved cells were dialyzed for 2 minutes before 151 
recording. Series resistance (Rseries) was compensated by at least 70% using the amplifier 152 
circuitry. The liquid junction potential (calculated using the Junction Potential tool in pCLAMP 153 
(Axon Instruments/Molecular Devices)) was relatively small (+4.3 mV) and therefore post-154 
recording adjustments of membrane potential were not performed. The voltage protocol used 155 
is outlined in Figure 2 and the cycle length for this protocol was 0.1 Hz.  156 
Patch-clamp recording analysis: Data were analyzed using Clampfit (Molecular 157 
Devices) and GraphPad Prism. As previously described in (Thomas et al. 2011) current-voltage 158 
relationships were generated by normalizing the maximal current densities at the end of each 159 
pulse-potential to cell capacitance. Peak-tail current density (PTCD) was analysed by 160 
normalizing the peak tail currents (in response to the prior test potential) to cell capacitance. 161 
The voltage-dependence of channel activation (or steady-state of activation) was determined 162 
by fitting the normalized peak tail current amplitudes (y/y max) versus a test potential (Vt) with 163 
a Boltzmann function (y/ymax = 1/(1 + exp[(V0.5 - Vt)/k])) (k indicates the slope factor). The V0.5 164 
value indicates the potential at which channel activation is half-maximal.  165 
 166 
2.4 Computational modelling of the effects of the G229D mutation on KCNQ1/KCNE1 167 
channel function  168 
The IKs formulation from the human ventricular O’Hara-Rudy dynamic model (ORd) 169 
model (O'Hara et al. 2011) was used to replicate the patch-clamp data (Supplementary 170 
Material). Least square curve fitting (lsqcurvefit) was combined with the Multi-Start algorithm 171 
in Matlab to find the parameters with optimised fitting results for the mutated IKs. Additional 172 
fitting details including model formulation are presented in the Supplementary Material. The 173 
optimised fitting results for IKs-HET (KCNQ1+G229D+KCNE1) and IKs-G229D 174 
(G229D+KCNE1) were inserted into the IKs current formulation of the ORd model, the human 175 
atrial (Grandi (Grandi et al. 2011) and Maleckar (Maleckar et al. 2009)) and Fabbri human 176 
sinus node (SN) models (Fabbri et al. 2017).  177 
To test whether the effects of our IKs-HET formulation on action potential duration 178 
(APD) and sinus node were stable, we also used the IKs/IKs-HET formulations of (Hasegawa et 179 
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al. 2014) to check the robustness of our results. Action Potential (AP) clamp simulations using 180 
three AP traces with different plateau levels were used to examine whether the effect of AP 181 
plateau on rapid delayed rectifier potassium current (IKr) was model specific by comparing the 182 
ORd, Maleckar, and Grandi models. 183 
 184 
2.5 In-silico populations of human ventricular cell and one-dimensional (1D) tissue fibers 185 
models 186 
A population of 2326 ORd-derived models calibrated with human in-vivo data was used 187 
to account for the effect of human electrophysiological variability as in (Zhou et al. 2016). An 188 
initial population of 10000 models was constructed by varying the main ionic conductances by 189 
up to ±100% using Latin Hypercube Sampling, including fast sodium current conductance 190 
(GNa), late sodium current conductance (GNaL), transient outward potassium current 191 
conductance (Gto), L-type calcium current conductance (GCaL), rapid delayed rectifier 192 
potassium current conductance (GKr), slow delayed rectifier potassium current conductance 193 
(GKs), inward rectifier potassium current conductance (GK1),  sodium-potassium pump current 194 
conductance (GNaK), sodium-calcium exchange current conductance (GNaCa), sarcoplasmic 195 
reticulum (SR) calcium release permeability (PJrel) and SR calcium re-uptake permeability 196 
(PJup). The initial population of 10000 models was calibrated using the human in vivo 197 
measurements described in (Zhou et al. 2016). The advantage of using a population of models 198 
rather than just a standard baseline model is that it provides scenarios of natural variability 199 
(Muszkiewicz et al. 2016), in particular for investigations on multiple disease phenotypes and 200 
variable penetrance (Passini et al. 2016).  201 
In the ORd model, the level of GKs is greatest in epicardial cells. Therefore, in order to 202 
evaluate the strongest possible effects in ventricles, we simulated the effect of the KCNQ1-203 
G229D mutation in epicardial fibers. A population of monodomain homogeneous epicardial 204 
1D fibers of 2cm was derived from the ORd single cell population. Pseudo-ECG signals were 205 
computed as the integral of spatial gradient of transmembrane potentials from all the points in 206 
the fibers (Gima and Rudy 2002). The tissue simulations and pseudo-ECG calculations were 207 
conducted in the open-source software CHASTE (Pitt-Francis et al. 2009) for 50 beats with a 208 
conductivity of 3.92 mS/cm to obtain a conduction velocity of 69 cm/s in the baseline ORd 209 
epicardial fiber. Transmural fibers consisted of 80% of endocardial cells and 20% of epicardial 210 
cells were also simulated for some representative cases with a conductivity of 1.19 mS/cm to 211 
obtain a transmural conduction velocity of 40 cm/s in the baseline ORd model.  212 
 213 
2.6 Construction and calibration of human atrial cell population of models  214 
Using a similar methodology as in (Britton et al. 2013), the nine current conductances 215 
of the Grandi atrial cell models (Grandi et al. 2011) were varied by up to ±100% using Latin 216 
Hypercube Sampling to generate an initial candidate population of 5000 models: GNa, GNaL, 217 
Gto, GCaL, GKr, GKs, GK1, ultrarapid delayed rectifier potassium current conductance (GKur), 218 
GNaK, and GNaCa. These currents were chosen based on their direct contributions to the 219 
regulation of APDs, and intracellular calcium fluxes were not varied due to their relatively 220 
small effects on APD (Muszkiewicz et al. 2018). After pacing each model under CL=1000ms 221 
for 500 beats, the experimental biomarker ranges from human atrial cells were used to select 222 
the models in range with the experimental data reported in (Sanchez et al. 2014). The models 223 
accepted under cycle length (CL) =1000ms were then paced under CL=2000ms and CL=500ms. 224 
The 917 models that did not display delayed afterdepolarizations, early afterdepolarizations or 225 
depolarization failure under all three CLs were accepted for further analysis. 226 
 227 
2.7 Construction and calibration of human sinus node cell population of models  228 
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An initial population of 5000 models was generated from the baseline Fabbri model 229 
(Fabbri et al. 2017) by using Latin hypercube sampling to introduce up to ±100% variations to 230 
12 current conductances and ion flux magnitudes: funny current conductance (Gf), GCaL, T-231 
type calcium current conductance (GCaT), GKr, GKs, Gto, GNa, GNaK, GNaCa, GKur, PJrel and PJup. 232 
These currents were chosen because both sarcolemmal currents and calcium handling affect 233 
spontaneous depolarization. After simulating each model for 1000s, 1046 models with a basic 234 
cycle length between 600ms and 1000ms (heart rate between 60-100 bpm) and a positive 235 
overshoot membrane potential were accepted for further analysis. The effects of IKs-HET in 236 
human sinus node models were classified into 3 categories: Robust (heart rate between 60-100 237 
bpm and a positive overshoot potential), Bradycardia (a positive overshoot potential and heart 238 
rate slower than 60 bpm), and Pacemaking failure (a negative maximum potential or a loss of 239 
spontaneous activity). 240 
 241 
2.8 Statistical analysis  242 
Patch-clamp experimental data was compared/analyzed using a one-way ANOVA with 243 
Bonferroni post-hoc test for multiple comparisons. Patch-clamp data was considered 244 
significantly different if P<0.05. Statistical analysis of in-silico modelling was conducted with 245 
Wilcoxon rank-sum test using Matlab, using a standard P<0.05, and differences in current 246 
conductances are reported in the figures and visualized as the differences of the medians of the 247 
distributions.  248 
 249 
3. RESULTS 250 
 251 
3.1 Clinical description of KCNQ1-G229D mutation carriers  252 
Patient A was seen after her daughter (Patient C) died unexpectedly whilst sleeping at 253 
21 years of age (Figure 1A). Patient A reported that as a teenager she had occasional periods 254 
of fainting but no reported exertional syncope. Her ECG was in sinus rhythm at 68 bpm (Figure 255 
1B&C) and her QTc was 465ms. It was noted following an ectopic beat that her QTc prolonged 256 
to 490ms.  257 
 258 
On the basis of the borderline QT prolongation and the death of her daughter she was 259 
genetically tested. Genetic testing found a previously reported pathogenic variant in KCNQ1 260 
c.686G>A (p.G229D) (Hasegawa et al. 2014). Based on this finding, other members of the 261 
family were genetically screened. Screening revealed that her mother (Patient B) and 262 
granddaughter (Patient D) are carriers of the KCNQ1 c.686G>A (p.G229D) mutation. Genetic 263 
testing for Patient C was not performed during autopsy but her relationship in the family proves 264 
that she was an obligate carrier. Clinical details for Patient D are unavailable. Patient B was 265 
first diagnosed with AF at 60 years of age and does not have a history of syncope. Her QTc 266 
values, measured in the presence of AF, were 440-446ms (Figure 1C). Our clinical data, and 267 
that reported by (Hasegawa et al. 2014) and (Moreton et al., 2013), indicate that KCNQ1 268 
c.686G>A (p.G229D) has high penetrance and that it is associated with AF, borderline LQT 269 
and sudden cardiac death. 270 
 271 
3.2 Effect of the G229D mutation on IKs channel function in-vitro and in-silico  272 
Patch clamp measurements show that G229D co-expression with KCNE1 (IKs-G229D) 273 
produced currents with marked instantaneous activation and tail currents that failed to 274 
deactivate (Figure 2A). To mimic the patient phenotype KCNQ1 and G229D were co-275 
expressed (with KCNE1) in heterozygous form (IKs-HET). The currents produced by IKs-HET 276 
possessed both instantaneous and slow activation components reflecting a combined phenotype 277 
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(Figure 2A) and the presence of G229D acted to shift the voltage-dependence of channel 278 
activation (V0.5) by approximately -35 mV (Figure 2D).  279 
 280 
Overall, our observed effects of G229D on channel function correlate well with the 281 
gain-of-function effect first reported by (Hasegawa et al. 2014). Using the electrophysiological 282 
data from the patch-clamp studies, we then modelled in-silico the effects of the G229D 283 
mutation on channel function. The fitting details for IKs-G229D and IKs-HET are shown in 284 
(Figures S1 and S2 in the Supplementary Material). The resulting IKs-G229D and IKs-HET 285 
models were then incorporated into the populations of human atrial, ventricular and sino-atrial 286 
cell models to investigate the complex electrophysiological consequences of the mutation.   287 
 288 
3.3 The predominant effect of IKs gain-of-function G229D mutation is APD shortening in 289 
both the atria and ventricle 290 
In the baseline human atrial Grandi model, IKs-HET caused significant reductions in 291 
APD (14.22%) and weakened the AP upstroke (Figure 3A), in agreement with (Hasegawa et 292 
al. 2014). Similarly, in the baseline ventricular ORd model, the presence of IKs-HET also 293 
weakened the AP upstroke and led to AP shortening by 9.83%. Both APD shortenings occurred 294 
because IKs-HET produced a much stronger current during the whole AP, and therefore 295 
repolarization proceeded more quickly. The degree of shortening in the Grandi atrial model 296 
was greater than in the ventricular model (Figure 3A&B), and even greater shortening of APD 297 
was seen in the Maleckar human atrial model (33.23% reduction, Figure S4 in the 298 
Supplementary Material). Therefore, the more significant APD shortening observed in human 299 
atrial models is not model-dependent. 300 
We investigated potential variability in the effect of IKs-HET formulations when 301 
inserted in populations of human ventricular and atrial models with variable ionic profiles. As 302 
an accumulation of IKs during increases in heart rate may be important for repolarisation 303 
(Viswanathan, Shaw, and Rudy 1999), we applied both slow and fast pacing CLs (2000ms, 304 
1000ms, 500ms, 333ms). For both populations of models, the most common effect of the 305 
mutation was APD shortening (Figure S5 in the Supplementary Material and Figure 3C&D). 306 
Under CL=1000ms, the median APD shortening in the human ventricular cell population was 307 
22ms, while in the human atrial cell population, the median shortening was 29ms (Figure 308 
3C&D). Thus, when considering ionic variability in the population, the G229D mutation 309 
induced greater APD shortening in human atria than in the ventricular models. Since the 310 
baseline Maleckar atrial model already showed an even greater APD shortening than the Grandi 311 
atrial model under the mutation, we did not construct a population of Maleckar atrial models 312 
to verify this phenomenon. Further analysis showed that the conductances of IKr, IKs and ICaL 313 
were the main determinants for the extent of ventricular APD shortening caused by IKs-HET 314 
(Figure 3E). Models with weak GCaL and GKr and strong GKs tended to present with more 315 
significant APD shortening under IKs-HET (Figure 3F). In the atrial population of models, a 316 
greater number of currents played roles in the regulation of APD shortening, and the most 317 
important factor was GKs (Figure 3E). Stronger GKs, GNaK and GCaL, and weaker GK1, Gto, GKur 318 
and GKr were associated with more significant APD shortening in the atrial cells (Figure 3E). 319 
 320 
3.4 Borderline APD prolongation may occur due to the interplay between IKr and HET-321 
IKs 322 
Although APD shortening was consistently observed under four pacing CLs (Figure S5 323 
in the Supplementary Material), some human ventricular models in the population resulted in 324 
APD prolongation in the presence of IKs-HET, especially at slower pacing rates (Figure 4A). 325 
Furthermore, the number of ventricular cell models that showed obvious APD prolongation 326 
(>5ms) was also increased as pacing rates became slower (no models under CL=500/333ms, 5 327 
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models under CL=1000ms and 25 models under CL=2000ms). Therefore, in the presence of 328 
KCNQ1-G229D, APD prolongation occurred more often at slower pacing rates.  329 
There was no significant difference between the WT APDs between the prolongation 330 
models and other models in the population. However, the AP peak membrane voltage was 331 
significantly reduced (Figure 4B) due to smaller baseline depolarization current conductances 332 
(GNa and GCaL) in the models displaying APD prolongation (Figure 4C). In addition, stronger 333 
baseline GKr was found in the models displaying APD prolongation at CL= 1000ms or 2000ms 334 
(Figure 4C). In the subgroup of models producing APD prolongation at CL=1000ms, replacing 335 
our IKs/IKs-HET formulations with the IKs/IKs-HET formulations of (Hasegawa et al. 2014) also 336 
generated consistent APD prolongation, supporting the robustness of these phenomena (Figure 337 
S6 in the Supplementary Material). 338 
To understand the ionic mechanisms underlying APD prolongation/shortening, we 339 
analysed the change of individual currents induced by the presence of the G229D mutation. 340 
The biggest differences in ionic currents for both prolongation and shortening were the increase 341 
of IKs (Figure 5A&B, middle panels) and the secondary decrease of IKr (Figure 5A&B, right 342 
panels). We selected two representative ventricular cell models with similar AP upstroke but 343 
one displaying shortening and the other prolongation with IKs-HET. The presence of IKs-HET 344 
affected the AP upstroke and led to a smaller peak membrane voltage and a lower plateau in 345 
both models. The reduction in IKr magnitude after G229D introduction was likely due to the 346 
reduced phase 2 AP plateau (Figure 5A&B, left panels).  347 
To verify whether this was model-specific, we conducted AP clamp simulations using 348 
different human IKr models. The IKr magnitude was consistently weaker under a smaller phase 349 
2 AP plateau in all models tested (Figure S7 in the Supplementary Material). For the human 350 
ventricular model displaying APD prolongation with IKs-HET, the decrease of IKr amplitude 351 
was slightly bigger than the increase of IKs amplitude under the IKs-HET condition (Figure 5A, 352 
middle and right panels). In contrast, in the human ventricular model displaying APD 353 
shortening, the augmentation of IKs was more significant than the inhibition of IKr (Figure 5B, 354 
middle and right panels).  355 
 Therefore, our explanation was that if the inhibition of IKr can overcome the 356 
augmentation of IKs, the presence of the G229D mutation could lead to an overall weaker 357 
repolarisation, and therefore a prolonged APD. Importantly, the prolongation models tended to 358 
have stronger IKr (Figure 4C), which was crucial for IKr reduction to be dominant under IKs-359 
HET. We also noticed that under slow pacing, the magnitude of IKs decreased, whereas IKr 360 
increased (Figure S8 in the Supplementary Material), which explained the increased number 361 
of models with APD prolongation at slow pacing. Overall, these findings further highlight that 362 
in the presence of the G229D mutation, ventricular APD prolongation is more likely to occur 363 
during bradycardia, particularly for strong IKr models. 364 
 365 
3.5 By counteracting action potential upstroke dynamics KCNQ1-G229D could promote 366 
tissue conduction abnormalities  367 
As illustrated earlier, the G229D mutation can reduce peak AP membrane voltage. We 368 
hypothesized that IKs-HET by counteracting AP upstroke dynamics (Figures 3A&B and 5A&B) 369 
could have important effects on the safety of conduction. In addition, we need to confirm 370 
whether the ionic mechanisms underlying APD prolongation in single cells hold true at the 371 
tissue level. Therefore, we investigated conduction and repolarization patterns in the presence 372 
of IKs-HET on the population of human ventricular one-dimensional (1D) fibers.  373 
The original ventricular 1D fiber showed a shorter QT interval with the G229D 374 
mutation (Figure 6A). In the population of 1D fibers, both significant QT prolongation and QT 375 
shortening can be observed (Figure 6B). 36 IKs-HET fibers showed QT prolongation compared 376 
to the corresponding IKs-WT fibers. In the QT prolongation fibers, the AP upstroke was delayed 377 
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at the end of the IKs-HET fiber (Figure 6C). In these cases, the QRS complex was wider, leading 378 
to a longer QT interval (Figure 6C, insert). 18 fibers developed depolarization abnormalities 379 
under IKs-HET, which meant no successful depolarization at the end of the fibers (Figure 6D), 380 
and the QT interval was also significantly affected (Figure 6D, insert). Similar results were 381 
obtained using transmural fibers (Figure S9 in the Supplementary Material). By comparing the 382 
parameters of the different groups of fibers, we found that the conductances of INa, ICaL, IKr, IKs, 383 
IK1, INaCa were significantly different. In both QT prolongation and depolarization abnormalities, 384 
the baseline INa was weak (Figure 6E). Models exhibiting depolarization abnormalities also 385 
tended to have weak baseline ICaL, IK1, INaCa and relatively strong IKs, which explained the 386 
danger of G229D mutation presence in their conduction (Figure 6E). The fibers showing QT 387 
prolongation had the strongest baseline IKr, which was consistent with the results from the 388 
cellular simulations.  389 
 390 
3.6 In silico simulations predict that KCNQ1-G229D is capable of promoting SN 391 
dysfunction by perturbing diastolic depolarization  392 
SN dysfunction and bradycardia has been reported for carriers of different KCNQ1 393 
gain-of-function mutations (S140G (Chen et al. 2003), V141M (Hong et al. 2005), R231C 394 
(Henrion et al. 2012), V241F (Ki et al. 2014) and F279I (Moreno et al. 2015)). Even though 395 
SN dysfunction has not been associated with KCNQ1-G229D (Hasegawa et al. 2014) or in the 396 
mutation carriers reported here, the effects of V141M on channel gating (Hong et al. 2005) are 397 
similar to those induced by the G229D mutation (this study and (Hasegawa et al. 2014)). 398 
Therefore, we investigated whether the G229D mutation can cause SN dysfunction in 399 
populations of sino-atrial node cells. In a recently published human SN model (Fabbri et al. 400 
2017), the normal SN model had a stable heart rate (HR) around 73.7 beats per minute (bpm) 401 
(Figure 7A). Starting from the same initial condition, when introduced IKs-HET produced an 402 
increasingly stronger IKs and slower HR, and the sinus rhythm was terminated after 625 seconds 403 
(Figure 7A). Plugging the IKs-HET model developed by (Hasegawa et al. 2014) into the 404 
simulation was confirmatory, as this model also led to sinus rhythm termination after 135 405 
seconds (Figure S10 in the Supplementary Material). 406 
SN activity was related to the interplay between the calcium subsystem and membrane 407 
potential in agreement with (Lakatta, Maltsev, and Vinogradova 2010). For successful 408 
spontaneous SN activation, a positive feedback loop between subsarcolemmal calcium (Casub) 409 
and Vm was needed for the diastolic depolarization. ICaL and INaCa provided the biggest 410 
depolarization current during the upstroke phase, and the net current excluding ICaL and INaCa 411 
was always positive (Figures S11 and S12 in the Supplementary Material). The activation of 412 
INaCa was regulated by Casub, and during diastolic depolarization, ICaL provided the biggest 413 
contribution for the initial accumulation of Casub (Figure S13 in the Supplementary Material). 414 
During normal diastolic depolarization, the total net current was inward, leading to very 415 
slow/limited activation of ICaL, accumulation of Casub and enhancement of INaCa (Figure 7B, left 416 
columns). At the end of diastolic depolarization, the augmentation of INaCa was strong enough 417 
to result in a significant increase in Vm that further activated ICaL, promoting faster 418 
depolarization in a positive feedback manner to initiate the upstroke phase (Figure 7B, left 419 
columns). 420 
In the SN cell model IKs-HET produced a much stronger repolarization current to 421 
counteract the diastolic depolarization process. At the time of diastolic depolarization 422 
interruption (time = 628.5s), IKs became so strong that the overall total current became outward. 423 
The membrane potential then started to decrease, along with the slow decay of ICaL, Casub, and 424 
INaCa activity (Figure 7B, right columns). Consequently, positive feedback during the 425 
depolarization phase was interrupted.  426 
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              To understand why the carriers of KCNQ1-G229D described in our study and those 427 
reported by (Hasegawa et al. 2014) do not present with bradycardia, we used a population of 428 
human SN models to explore the effects of heterogeneity in ion channel expression. In the 1046 429 
human SN cell models, 168 models are robust to IKs-HET, 153 models became bradycardic, 430 
and the rest (725 models) displayed pacemaking failure. By comparing the parameters, we 431 
identified differences in IKs, ICaL, INaCa, INaK and IKr conductances between models displaying 432 
different phenotypes (Figure 7C). As expected, the Pacemaking failure group had the highest 433 
level of IKs-HET. A stronger ICaL in the Robust and Bradycardia groups can counteract the 434 
changes caused by IKs-HET and enable safer spontaneous activation. In the Robust group, a 435 
stronger inward INaCa and a weaker outward INaK contributed to maintaining negative total 436 
current during diastolic depolarization. In addition, a stronger IKr in Robust and Bradycardia 437 
groups can counteract the effect of high level ICaL, preventing excessive APD prolongation 438 
(Figure 7C). 439 
 440 
4. DISCUSSION 441 
 442 
In this present study, we investigate the complex phenotypic implications of a gain-of-443 
function mutation in IKs (KCNQ1-G229D) through a combination of computational modelling 444 
and simulation and patch clamp experimental characterisation, as well as clinical presentation. 445 
We describe members of a family that carry KCNQ1-G229D and report that this mutation 446 
underlies a complex phenotype characterized by AF, borderline LQT and sudden death. Our 447 
clinical findings correlate well with those reported by (Hasegawa et al. 2014) and (Moreton et 448 
al., 2013). We explored the pathogenic role of this mutation using a combination of in-vitro 449 
experiments and in-silico simulations in human SN, atrial and ventricular models. In addition 450 
to providing further evidence supporting the role of G229D in promoting AF as shown in 451 
previous studies, we expand our knowledge of G229D and other gain-of-function KCNQ1 452 
mutations in additional ways. Firstly, we present the first mechanistic investigation into why 453 
the G229D mutation (and perhaps other KCNQ1 gain-of function mutations) could be 454 
associated with a borderline LQT phenotype. Secondly, we demonstrate that the gain-of-455 
function mutation could promote pro-arrhythmic conduction abnormalities by counteracting 456 
the AP depolarization phase and reducing conduction safety. This could be a critical 457 
mechanism of sudden cardiac death. Thirdly, we utilize populations of human SN models to 458 
provide detailed mechanistic predictions which highlight that KCNQ1-G229D could underlie 459 
SN dysfunction. Finally, our findings provide plausible reasons for observed phenotypic 460 
variability and insights for the clinical management of these patients.  461 
 462 
4.1 A potential explanation for G229D associated QT prolongation  463 
The mechanisms underlying the presence of borderline LQT in G229D carriers 464 
((Hasegawa et al. 2014), (Moreton et al., 2013) and this study) and other KCNQ1 gain-of-465 
function mutations (particularly S140G) (Chen et al. 2003; Lundby et al. 2007; Bartos et al. 466 
2011; Bartos et al. 2013) are unclear. We used a population of human ventricular cell models 467 
to investigate the complex interactions between different currents in the presence of G229D. 468 
In addition to APD shortening produced by the standard ventricular model, a subset of the 469 
models in the population exhibited APD prolongation. We found that APD prolongation was 470 
caused by an interplay between a decrease in IKr activity and increase in IKs activity at slow 471 
pacing. Based on our simulations, the instantaneous current component produced by KCNQ1-472 
G229D reduces the magnitude of the AP upstroke which leads to a smaller peak membrane 473 
voltage and a lower plateau. Consequently, the presence of a lower plateau acts to decrease the 474 
activity of IKr which, in turn, acts to prolong APD. In our fibers showing QT prolongation at 475 
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the tissue level, IKr tended to be stronger, suggesting the IKr/IKs interplay mechanism, originally 476 
identified in single cells, also holds true at the tissue level. 477 
 478 
4.2 KCNQ1-G229D may induce defects in conduction  479 
The 1D fiber results also indicate that the presence of KCNQ1-G229D could impair 480 
myocardial conduction. Although QRS widening in fibers was not observed clinically in 481 
mutation carriers, whole ventricle simulations have shown that QRS width is more sensitive to 482 
the activation pattern in the conduction system rather than myocardial propagation (Cardone-483 
Noott et al. 2016). Therefore, local conduction abnormalities in the myocardium may still be 484 
present even with normal QRS width. Local or regional conduction abnormalities may also 485 
occur due to heterogeneous expression of KCNQ1/G229D throughout the ventricles 486 
(Viswanathan, Shaw, and Rudy 1999; Liu and Antzelevitch 1995). Although the fiber 487 
simulations we used do not account for the full heterogeneity known to span the human 488 
ventricles, they do provide a rough approximation of tissue behaviour. Despite these potential 489 
limitations, our findings emphasize that G229D could enhance regional differences in 490 
conduction and this could contribute to the substrate required for the formation of a lethal 491 
arrhythmia.  492 
 493 
4.3 In-silico modelling using human models provides explanations for SN and atrial 494 
dysfunction   495 
Our human SN model simulations predict that the G229D mutation is likely to underlie 496 
SN dysfunction and that this could increase the risk of sinus arrest. By examining variations in 497 
ionic current density, our population of SN models may also provide plausible explanations as 498 
to why a dysfunctional SN phenotype was not seen by (Hasegawa et al. 2014) or in the mutation 499 
carriers we report. Based on the mechanisms revealed in this study and those of (Fabbri et al. 500 
2017; Whittaker et al. 2018), disturbed SN activity could be a general action of KCNQ1 gain-501 
of-function mutations that alter channel gating in a similar fashion.  502 
Mechanistically, the G229D mutation has been postulated to cause AF by promoting 503 
atrial APD shortening (Hasegawa et al. 2014) and two and three-dimensional tissue models 504 
have described that this mutation promotes the sustainment of re-entrant waves thereby 505 
increasing susceptibility to atrial arrhythmia (Zulfa et al. 2016). In our baseline and population 506 
of models, the G229D mutation results in atrial and ventricular AP shortening, but the average 507 
degree of shortening is less for ventricular than atrial APs, which agrees with the findings of 508 
(Hasegawa et al. 2014) and implies a more prominent effect of the mutation on the human atria.  509 
 510 
4.4 Clinical implications for KCNQ1-G229D carriers  511 
KCNQ1-G229D presents in adults largely as AF, and Class I drugs such as flecainide 512 
and quinidine may be prescribed. Based on our simulation results, KCNQ1-G229D could 513 
impair conduction by counteracting AP upstroke, and class I sodium channel blockers could 514 
exacerbate this. Furthermore, our simulations predict that this mutation could underlie SN 515 
dysfunction which has been postulated to act as a substrate for the development of AF (Duhme 516 
et al. 2013). Indeed, a trend in disease progression from bradycardia in to persistent AF has 517 
been reported for patients that carry the KCNQ1 gain-of-function mutation V241F (Ki et al. 518 
2014). As revealed by our SN simulations, ICaL played a crucial role in the maintenance of 519 
normal sinus rhythm in the presence of the G229D mutation. Therefore, drugs with class IV 520 
calcium channel blocking actions could unravel bradycardia in G229D mutation carriers with 521 
normal sinus rhythm. 522 
Our simulations showed that QT prolongation was primarily observed during 523 
bradycardia implying that the prevention of bradycardia to maintain sinus rhythm should be 524 
considered in the management of mutation carriers. The use of drugs with a negative 525 
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chronotropic effect, such as beta-blockers, should therefore be reviewed and device 526 
implantation considered for KCNQ1 gain-of-function mutation carriers that present with 527 
bradycardia. 528 
Another intriguing observation is that some G229D mutation carriers have died 529 
suddenly whilst sleeping (reported in this study and (Moreton et al., 2013)). Sudden cardiac 530 
arrest during sleep has also been reported for a carrier of KCNQ1-R231H (Bartos et al. 2013). 531 
Unfortunately, we do not have the necessary clinical information to establish the precise 532 
mechanisms underlying these deaths. In LQT1, cardiac arrest normally occurs during exercise 533 
and sudden cardiac death during sleep is more a feature of LQT3 (Schwartz et al. 2001). 534 
Therefore, we can propose two possible mechanisms: sinus arrest without escape rhythms or a 535 
lethal arrhythmia caused by severe QT prolongation. It is worth noting that sinus arrest, due to 536 
SN dysfunction, is an unusual cause of death and SN disease in the absence of symptoms is not 537 
generally considered prognostically important. In view of these considerations we suspect that 538 
the most likely mechanism of sudden death in these patients is the promotion of a lethal 539 
arrhythmia by QT prolongation and/or conduction block.  540 
 541 
4.5 Limitations of the study 542 
The effects of the G229D mutation on IKs channel function were modelled in a 543 
heterologous expression system. Therefore, it is possible that the expression and kinetics of the 544 
mutant channel complex could be distinct in cardiomyocytes. We were limited to this model 545 
because: 1) It is not possible to use mice or rats as a model as these species do not use IKs for 546 
cardiac repolarization in adult life (Nerbonne 2014). 2) The generation of transgenic rabbit 547 
models of KCNQ1 mutations (Brunner et al. 2008), would be prohibitively expensive and the 548 
higher heart rate of this species would likely confound modelling the effects of the mutation 549 
on the sinus node. 3) The current utility of human induced pluripotent stem derived 550 
cardiomyocytes (hiPSC-CMs) for examining IKs function has been questioned and this may 551 
relate to their relative immaturity (Christ, Horvath, and Eschenhagen 2015). We would also 552 
like to highlight that although we propose an explanation for the borderline LQT seen in 553 
carriers of the G229D mutation the observed APD prolongations in the population of models 554 
subset were relatively mild. This could relate to the potential differences between the function 555 
of the mutant channel complex in the heterologous expression system versus in cardiomyocytes 556 
or alternatively it could imply that other mechanisms contributing to QT prolongation exist. In 557 
the future, the validation of our in-silico predictions in a physiological system is warranted. 558 
hiPSC-CM technology is rapidly advancing, and we hope that in time we will be able to use 559 
this model to study the effects of the G229D mutation in human cardiomyocytes that possess 560 
adult-like and chamber/region specific electrophysiological properties. 561 
 562 
5. CONCLUSION 563 
By using a combined in vitro and in silico approach we have explored how the KCNQ1 564 
mutation G229D can underlie the reported phenotype of AF and borderline QT prolongation. 565 
In addition, our modelling results suggest that the G229D mutation can cause conduction 566 
abnormalities, and can underlie SN dysfunction. Importantly, our results suggest that for 567 
G229D mutation carriers (and perhaps for other KCNQ1 gain-of-function mutation carriers), 568 
the prescription of beta-blockers, class I sodium channel blockers and compounds with class 569 
IV calcium channel blocking properties should be used with caution.  570 
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Figure 1. Partial pedigree and clinical information for members of a family carrying the 756 
KCNQ1 mutation G229D (c.686G>A/p.G229D). A, Partial mini pedigree of a British family 757 
that present with a complex arrhythmic phenotype that includes sudden cardiac death (SCD), 758 
atrial fibrillation (AF) and borderline QT prolongation. Circles indicate female family 759 
members. B, Lead II and V5 electrocardiograms (ECGs) from Patient (A) with borderline QT 760 
prolongation but not AF. C, Clinical characteristics of carriers of the KCNQ1-G229D mutation. 761 
*= Not genetically tested but obligate carrier of the KCNQ1-G229D mutation (c.686G>A 762 
(p.G229D)) based on position in the family. Please refer to Panel A for the location of each 763 
patient in the pedigree. NK= Not Known; NA= Not Available.  764 
 765 
Figure 2. KCNQ1-G229D dramatically alters the biophysical properties of the 766 
KCNQ1/KCNE1 (IKs) channel. A, Representative traces of the currents produced by wild-type 767 
(WT) KCNQ1 (KCNQ1+KCNE1: IKs-WT) or G229D when expressed homozygously 768 
(G229D+KCNE1: IKs-G229D) or in heterozygous fashion (KCNQ1+G229D+KCNE1: IKs-769 
HET). The effect of the G229D mutation on channel function, in CHO-K1 cells, was analysed 770 
by whole-cell patch-clamp. In all cases, to recapitulate the IKs current, KCNE1 was co-771 
expressed. The zero-current level (0 pA) is indicated by the grey line. The voltage protocol 772 
used to elicit these currents is inset in panel A. B, Mean current-voltage relationships (Current 773 
Density). C, Peak-tail current density (PTCD). D, Normalised voltage-dependent activation 774 
curves (V0.5) (in mV). The activation curves are fit with Boltzmann functions (solid lines). E, 775 
Black and grey arrows indicate the points where the current density signals (Current density 776 
(CD) and PTCD were used to calculate the corresponding biomarkers for analysis and fitting. 777 
Data are presented as mean ± SEM. (n=8-12). N.D. = Not Determined. * indicates significantly 778 
different from WT control value (P<0.05) (One-way ANOVA analysis with Bonferroni post 779 
hoc test). 780 
 781 
Figure 3. In-silico simulations of the effects of KCNQ1-G229D on human ventricular and 782 
atrial action potentials. The effect of the G229D mutation on membrane voltage (Vm, mV, 783 
insets showing peak upstroke) and IKs (μA/μF) in the Grandi human atrial cell model (A) and 784 
the ORd human ventricular epicardial cell model (B). Comparison of absolute APD change 785 
(ΔAPD =APDIKs-HET – APDIKs-WT, C) and relative APD change (ΔAPD/APDIKs-WT, D) after 786 
introducing IKs-HET between Grandi atrial population of models and ORd ventricular 787 
population of models at CL=1000ms. (***: P<0.001) (Wilcoxon rank-sum test). E, Partial 788 
correlation analysis between ΔAPD at CL=1000ms and current conductances in the population 789 
of atrial and ventricular models. The partial correlation coefficients (PCC) are indicated by the 790 
color scale, where red implies a strong positive correlation and blue implies a strong negative 791 
correlation. F, Relationship between the conductances of IKr, IKs and ICaL and the ΔAPD in the 792 
ORd population. 0 to 2 represent the scaling factors for the baseline conductances in the ±100% 793 
range. 794 
 795 
Figure 4. KCNQ1-G229D can lead to ventricular APD prolongation at slow pacing rates. A, 796 
APD prolongations under 4 pacing rates (ΔAPD =APD-IKs-HET – APD-IKs-WT). B, 797 
Comparison of the WT peak membrane voltage between the models that showed or did not 798 
show APD prolongation under IKs-HET at CL=1000ms. C, Parameter comparison between 799 
models that showed APD prolongation at CL=1000ms or 2000ms and those that did not show 800 
APD prolongation under IKs-HET. The y axis represents the scaling factors in the ±100% range 801 
(0 to 2) to the original baseline ORd model current conductances (***: P<0.001) (Wilcoxon 802 
rank-sum test). Black points indicate extreme values that lie more than 1.5 times the 803 
interquartile range away from the top (the 75th percentile) or bottom (the 25th percentile) of 804 




Figure 5. KCNQ1-G229D can lead to ventricular APD prolongation by altering the interplay 807 
between IKr and IKs. Effects of KCNQ1-G229D mutation (IKs-HET) on IKr and IKs in 808 
representative models displaying (A) APD prolongation and (B) APD shortening, at 809 
CL=1000ms. The arrows indicate the change of current magnitude after introducing G229D. 810 
In A, the decrease of IKr is more significant than the increase of IKs, while in B the opposite 811 
occurs. 812 
 813 
Figure 6. KCNQ1-G229D can impair conduction safety by counteracting action potential 814 
upstroke. A, Pseudo-ECG of the original ORd human homogeneous epicardial 1D fiber. B, 815 
Longer and shorter QT intervals are possible in the presence of the G229D mutation (IKs-HET) 816 
in Pseudo-ECGs of the population of human epicardial 1D fiber. C, APs of a fiber that showed 817 
slower conduction in the presence of the G229D mutation, with the corresponding pseudo-818 
ECG as an insert. D, APs of a fiber that showed a depolarization abnormality in the presence 819 
of the G229D mutation, with the corresponding pseudo-ECG as an insert. (C and D) There are 820 
100 nodes in the whole fiber, and Node 20 (dashed lines) and Node 80 (solid lines) are at sites 821 
near the beginning and the end of the fiber. E, Comparisons of ionic current conductances 822 
between the fibers that showed shorter QT, longer QT and depolarization abnormalities in the 823 
presence of G229D (***: P<0.001, **: P<0.01 and *: P<0.05) (Wilcoxon rank-sum test). Black 824 
points indicate extreme values that lie more than 1.5 times the interquartile range away from 825 
the top (the 75th percentile) or bottom (the 25th percentile) of the box. 826 
 827 
Figure 7. KCNQ1-G229D can cause sinus node dysfunction. A, IKs-HET presence results in a 828 
loss of sinus rhythm. B, Comparison between the last spontaneous activated beat and the failing 829 
process under IKs-HET. The red circles in the right columns indicate the time =628.5s when 830 
diastolic depolarization was interrupted, and membrane potential started to decrease. C, 831 
Parameter comparison between Robust, Bradycardia and Pacemaking failure groups under IKs-832 
HET (***: P<0.001, **: P<0.01, *: P<0.05) (Wilcoxon rank-sum test). Black points indicate 833 
extreme values that lie more than 1.5 times the interquartile range away from the top (the 75th 834 
percentile) or bottom (the 25th percentile) of the box. 835 
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